PRTH-101

CAMBRIDGE, Mass.--( BUSINESS WIRE )-- Incendia Therapeutics , a clinical-stage biotechnology company discovering and developing novel monoclonal antibody therapies that disrupt the tumor microenvironment (TME) to improve cancer outcomes, today announced the appointment of Bradford Smith as Chief Financial Officer (CFO). Smith is an accomplished financial executive with more than 30 years of strategic and operational leadership in emerging growth and commercial stage healthcare companies. He has previously served in CFO roles with publicly traded and privately held companies that include Homology Medicines, Ocular Therapeutix, OmniGuide, NeuroMetrix, and Synarc. Smith also serves as a board member and Audit Committee Chair for Lyra Therapeutics (Nasdaq: LYRA) and eGenesis. He holds a Bachelor of Science degree in biology from Tufts University and a Master of Business Administration from the Whittemore School at the University of New Hampshire. “Brad’s deep experience in company building, infrastructure, and finance will be critical as we advance our clinical-stage and pipeline programs and grow the organization” said Wendye R. Robbins, M.D., president and CEO of Incendia. “During the course of his career, Brad has raised more than $1 billion of financing and delivered value for investors and patients. I am delighted to welcome him to the Incendia team.” “I’m thrilled to join Incendia as the company advances its pipeline of therapies that disrupt the tumor microenvironment, enabling better treatment of solid tumors,” said Smith. “I look forward to working with Wendye and the talented team at Incendia. It’s an exciting time as the company advances its lead program toward phase 2 and pipeline programs prepare for the clinic.” Smith will report to Dr. Robbins as the Company’s first CFO. He will oversee all financial functions within Incendia, including equity financing, investor relations, business development, financial planning and analysis, budgeting and forecasting, and accounting. About Incendia Therapeutics Incendia Therapeutics is a clinical-stage biotechnology company discovering and developing novel monoclonal antibody therapies that reengineer the tumor microenvironment (TME) to improve cancer outcomes. The company’s approach targets immune-excluded solid tumors, an identifiable, prevalent tumor phenotype with high treatment relapse rates. By breaking down barriers in the TME, immune cells can reach tumors and improve treatment outcomes in solid cancers. The Company’s most advanced investigational therapeutic, PRTH-101, is in a Phase 1c clinical trial for the treatment of patients with advanced solid tumors. The Company is targeting initiation of Phase 2 in 2H2025. For more information visit incendia.com and LinkedIn .

Innovative Assay Aims to Enhance Patient Outcomes through Precision Medicine PALO ALTO, Calif. and CAMBRIDGE, Mass., Oct. 28, 2024 /PRNewswire/ -- DELFI Diagnostics, Inc., a developer of accessible blood-based tests that deliver a new way to enhance cancer detection, today announced that Incendia Therapeutics will use the DELFI-TF Monitoring assay as part of their suite of assays for evaluation of treatment response and disease progression in patients enrolled in their Phase I clinical trial (NCT05753722). Continue Reading Incendia Therapeutics is discovering and developing a novel class of experimental therapeutics that reprogram the tumor microenvironment (TME). "Incendia is committed to the development of novel, precision medicines for patients in need. Innovative products, such as those being developed by DELFI, will aid in the efficient progress of those medicines through the clinic," said Susan Macdonald, PhD, SVP Nonclinical Development & Strategy at Incendia Therapeutics, commenting on how the relationship leverages the strengths of both companies to bring a state-of-the-art detection tool to scientific researchers looking to develop precise treatment monitoring. "The DELFI-TF assay provides a unique, cost-effective approach to monitoring cfDNA from patients in clinical research studies, providing evidence of the efficacy of a New Molecular Entity (NME) in the earliest phases of clinical development," said DELFI Diagnostics Co-Founder and Chief Scientific Officer, Nicholas Dracopoli. "The DELFI-TF assay will provide Incendia with valuable insights to help them manage their Phase 1 program." One key advantage of the DELFI TF assay is that it requires under 1 mL of plasma — considerably less than the volume needed for other cfDNA assays. This low volume is particularly beneficial in early clinical studies that require large volumes of blood for other assessments, such as pharmacokinetic (PK) analyses. About DELFI Diagnostics DELFI Diagnostics is developing next-generation, blood-based tests that are accurate, accessible, and deliver a new way to help detect cancer. DELFI tests are built to solve the highest-burden population health issues, including in historically underserved demographics, and have the potential to save lives on a global scale. FirstLook Lung, for individuals eligible for lung cancer screening, is our first laboratory-developed screening test and requires a simple blood draw that can be incorporated with routine blood work. The test is based on fragmentomics, the discovery that cancer cells are more chaotic than normal cells and, when they die, leave behind tell-tale patterns and characteristics of cell-free DNA (cfDNA) fragments in the blood. The DELFI platform applies advanced machine-learning technology to whole-genome sequencing data to assess individuals' cfDNA fragments against populations with and without cancer. FirstLook Lung uses these millions of data points to reliably identify individuals who may have cancer detected through low-dose CT, including early-stage disease, with a negative predictive value of 99.8 percent. This test has not been cleared or approved by the FDA. To learn more about the FirstLook Lung test, visit or . About Incendia Therapeutics Incendia Therapeutics is discovering and developing a novel class of experimental therapeutics that reprogram the tumor microenvironment (TME). Incendia's platform is based on rigorous, groundbreaking research involving spatial characterization of the tumor microenvironment, multi-omics data integration, and extensive preclinical testing. The Company's most advanced experimental molecule, PRTH-101, is in a Phase 1 clinical trial for the treatment of patients with advanced solid tumors. For more information visit incendiatx.com and LinkedIn. SOURCE DELFI Diagnostics WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED